

TARGETED GENETICS CORP /WA/

Form 4/A

July 29, 2005

**FORM 4****UNITED STATES SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549**

Check this box  
if no longer  
subject to  
Section 16.  
Form 4 or  
Form 5  
obligations  
may continue.  
See Instruction  
1(b).

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF  
SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,  
Section 17(a) of the Public Utility Holding Company Act of 1935 or Section  
30(h) of the Investment Company Act of 1940

## OMB APPROVAL

OMB  
Number: 3235-0287  
Expires: January 31,  
2005  
Estimated average  
burden hours per  
response... 0.5

(Print or Type Responses)

1. Name and Address of Reporting Person \*  
**BIAGEN IDEC INC**

2. Issuer Name **and** Ticker or Trading  
Symbol  
**TARGETED GENETICS CORP  
/WA/ [TGEN]**

5. Relationship of Reporting Person(s) to  
Issuer

(Check all applicable)

(Last) (First) (Middle)

14 CAMBRIDGE CENTER

(Street)

CAMBRIDGE, MA 02142

(City) (State) (Zip)

3. Date of Earliest Transaction  
(Month/Day/Year)  
07/25/2005

\_\_\_\_ Director \_\_\_\_X\_\_\_\_ 10% Owner  
\_\_\_\_ Officer (give title below) \_\_\_\_ Other (specify below)

4. If Amendment, Date Original  
Filed(Month/Day/Year)  
07/27/2005

6. Individual or Joint/Group Filing(Check  
Applicable Line)  
\_\_\_\_ Form filed by One Reporting Person  
\_X\_ Form filed by More than One Reporting  
Person

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

| 1. Title of Security (Instr. 3) | 2. Transaction Date (Month/Day/Year) | 2A. Deemed Execution Date, if any (Month/Day/Year) | 3. Transaction Code (Instr. 8) | 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) |        |            | 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) | 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 7. Nature of Indirect Beneficial Ownership (Instr. 4) |
|---------------------------------|--------------------------------------|----------------------------------------------------|--------------------------------|-------------------------------------------------------------------|--------|------------|-----------------------------------------------------------------------------------------------|----------------------------------------------------------|-------------------------------------------------------|
|                                 |                                      |                                                    | Code                           | V                                                                 | Amount | (A) or (D) | Price                                                                                         |                                                          |                                                       |
| Common Stock, \$0.01 Par Value  | 07/25/2005                           |                                                    | S                              |                                                                   | 8,500  | D          | \$ 0.79                                                                                       | 11,966,948 <sup>(1)</sup>                                | I by Biogen Idec MA, Inc. <sup>(2)</sup>              |
| Common Stock, \$0.01 Par Value  | 07/26/2005                           |                                                    | S                              |                                                                   | 2,500  | D          | \$ 0.81                                                                                       | 11,964,448 <sup>(1)</sup>                                | I by Biogen Idec MA, Inc. <sup>(2)</sup>              |
| Common Stock, \$0.01 Par Value  | 07/26/2005                           |                                                    | S                              |                                                                   | 12,500 | D          | \$ 0.82                                                                                       | 11,951,948 <sup>(1)</sup>                                | I by Biogen Idec MA, Inc. <sup>(2)</sup>              |

|                                         |            |   |        |   |            |                   |   |                                   |
|-----------------------------------------|------------|---|--------|---|------------|-------------------|---|-----------------------------------|
| Common<br>Stock,<br>\$0.01 Par<br>Value | 07/26/2005 | S | 10,640 | D | \$<br>0.83 | 11,941,308<br>(1) | I | by Biogen<br>Idec MA,<br>Inc. (2) |
| Common<br>Stock,<br>\$0.01 Par<br>Value | 07/26/2005 | S | 11,200 | D | \$<br>0.85 | 11,930,108<br>(1) | I | by Biogen<br>Idec MA,<br>Inc. (2) |
| Common<br>Stock,<br>\$0.01 Par<br>Value | 07/26/2005 | S | 25,660 | D | \$<br>0.86 | 11,904,448<br>(1) | I | by Biogen<br>Idec MA,<br>Inc. (2) |
| Common<br>Stock,<br>\$0.01 Par<br>Value | 07/26/2005 | S | 2,500  | D | \$<br>0.87 | 11,901,948<br>(1) | I | by Biogen<br>Idec MA,<br>Inc. (2) |

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.**

SEC 1474  
(9-02)

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned**  
(e.g., puts, calls, warrants, options, convertible securities)

| 1. Title of<br>Derivative<br>Security<br>(Instr. 3) | 2. Conversion<br>or Exercise<br>Price of<br>Derivative<br>Security | 3. Transaction Date<br>(Month/Day/Year) | 3A. Deemed<br>Execution Date, if<br>any<br>(Month/Day/Year) | 4. Transaction<br>Code<br>(Instr. 8) | 5. Number<br>of<br>Derivative<br>Securities<br>Acquired<br>(A) or<br>Disposed<br>of (D)<br>(Instr. 3,<br>4, and 5) | 6. Date Exercisable and<br>Expiration Date<br>(Month/Day/Year) | 7. Title and<br>Amount of<br>Underlying<br>Securities<br>(Instr. 3 and 4) | 8. Price of<br>Derivative<br>Security<br>(Instr. 5) | 9. Number of<br>Derivative<br>Securities<br>Beneficially<br>Owned<br>Following<br>Transaction<br>(Instr. 6) |
|-----------------------------------------------------|--------------------------------------------------------------------|-----------------------------------------|-------------------------------------------------------------|--------------------------------------|--------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------|---------------------------------------------------------------------------|-----------------------------------------------------|-------------------------------------------------------------------------------------------------------------|
|                                                     |                                                                    |                                         |                                                             | Code                                 | V (A) (D)                                                                                                          | Date<br>Exercisable                                            | Expiration<br>Date                                                        | Title                                               | Amount<br>or<br>Number<br>of<br>Shares                                                                      |

## Reporting Owners

| Reporting Owner Name / Address         | Relationships |           |         |       |
|----------------------------------------|---------------|-----------|---------|-------|
|                                        | Director      | 10% Owner | Officer | Other |
| BIOGEN IDEC INC<br>14 CAMBRIDGE CENTER |               |           | X       |       |

CAMBRIDGE, MA 02142

BIOGEN IDEC MA INC  
14 CAMBRIDGE CENTER  
CAMBRIDGE, MA 02142

X

## Signatures

Raymond G. Arner, Acting General Counsel, Biogen  
Idec Inc.

07/29/2005

\_\_Signature of Reporting Person

Date

Michael F. Phelps, Treasurer, Biogen Idec MA, Inc.

07/29/2005

\_\_Signature of Reporting Person

Date

## Explanation of Responses:

\* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) This amendment to the Form 4 originally filed on July 27, 2005 (the "Original Form 4") amends and restates the Original Form 4 in its entirety and is being filed solely to correct the amount of Targeted Genetics Corporation common stock beneficially owned by the reporting person. The Original Form 4 inadvertently overreported the reporting person's beneficial ownership of Targeted Genetics Corporation common stock by 25,000 shares.

(2) Shares are owned indirectly by Biogen Idec Inc. and directly by its wholly-owned subsidiary Biogen Idec MA Inc., fka Biogen, Inc.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.